The drugmaker is quietly sounding out potential bidders for a possible sale of Mead Johnson, its baby formula business, which is valued at between $7 billion and $9 billion, The Financial Times reports. The Mead Johnson unit is best known for its Enfamil and Enfalac range of infant formula.

Those approached include PepsiCo, Danone, Nestlé, Kraft and Heinz as way to test the appetite for a formal auction, the paper writes, citing unnamed people familiar with the effort. Bristol-Myers has also put out feelers to pharmaceutical companies which have nutritional divisions, including Johnson & Johnson, GlaxoSmithKline and Novartis, those people tell the paper. An actual sales process hasn’t begun, though.

The move comes less than three months after the drugmaker disclosed plans to conduct a strategic review of its nutritionals business and ConvaTec, a wound care products supplier, in order to focus on becoming a global biopharmaceutical company. Bristol-Myers declined to comment, but said it “continued to evaluate its strategic options with Mead Johnson and ConvaTec.”

Morgan Stanley and Citicorp, which have been tapped to auction ConvaTec, are understood to have extended the deadline for second round bids to June, after failing to attract enough interested bidders, the Times writes. So far, 3M, the diversified technology company which also has a healthcare business including wound care, has emerged as one of the strongest bidders.